Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1989 2
1990 5
1991 7
1992 4
1993 2
1996 2
1997 2
1998 1
1999 1
2000 1
2001 1
2003 3
2004 1
2005 1
2006 2
2009 6
2010 3
2011 2
2012 4
2013 7
2014 9
2015 6
2016 10
2017 9
2018 7
2019 8
2020 9
2021 6
2022 7
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Acne in adolescents.
Gebauer K. Gebauer K. Aust Fam Physician. 2017 Dec;46(12):892-895. Aust Fam Physician. 2017. PMID: 29464224 Free article. Review.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Acne variants.
Gebauer K. Gebauer K. Am J Clin Dermatol. 2000 May-Jun;1(3):187-9. doi: 10.2165/00128071-200001030-00006. Am J Clin Dermatol. 2000. PMID: 12094771 No abstract available.
5-Fluorouracil-induced pseudoporphyria.
Laidman PJ, Gebauer K, Trotter J. Laidman PJ, et al. Among authors: gebauer k. Aust N Z J Med. 1992 Aug;22(4):385. doi: 10.1111/j.1445-5994.1992.tb02154.x. Aust N Z J Med. 1992. PMID: 1359863 No abstract available.
Non-infectious skin disease in Indigenous Australians.
Heyes C, Tait C, Toholka R, Gebauer K. Heyes C, et al. Among authors: gebauer k. Australas J Dermatol. 2014 Aug;55(3):176-84. doi: 10.1111/ajd.12106. Epub 2013 Oct 8. Australas J Dermatol. 2014. PMID: 25117159 Review.
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement.
Mastacouris N, Tannenbaum R, Strunk A, Koptyev J, Aarts P, Alhusayen R, Bechara FG, Benhadou F, Bettoli V, Brassard A, Brown D, Choon SE, Coutts P, da Silva DLF, Daveluy S, Dellavalle RP, Del Marmol V, Emtestam L, Gebauer K, George R, Giamarellos-Bourboulis EJ, Goldfarb N, Hamzavi I, Hazen PG, Horváth B, Hsiao J, Ingram JR, Jemec GBE, Kirby JS, Lowes MA, Marzano AV, Matusiak L, Naik HB, Okun MM, Oon HH, Orenstein LAV, Paek SY, Pascual JC, Fernandez-Peñas P, Resnik BI, Sayed CJ, Thorlacius L, van der Zee HH, van Straalen KR, Garg A. Mastacouris N, et al. Among authors: gebauer k. JAMA Dermatol. 2023 Nov 1;159(11):1258-1266. doi: 10.1001/jamadermatol.2023.3282. JAMA Dermatol. 2023. PMID: 37755725
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
van Huizen AM, Menting SP, Gyulai R, Iversen L, van der Kraaij GE, Middelkamp-Hup MA, Warren RB, Spuls PI; SPIN MTX Consensus Survey Study Group; Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse AC, Carija A, Akman-Karakas A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado-García C, Hong CH, Griffiths CEM, Vestergaard C, Echeverría CM, de la Cruz C, Conrad C, Törocsik D, Drvar DL, Balak D, Jullien D, Appelen D, Kim DH, de Jong EMGJ, El Gamal E, Laffitte E, Mahé E, Sonkoly E, Colombo EP, Vilarrasa E, Willaert F, Novoa FD, Handjani F, Valenzuela F, Vílchez-Márquez F, Gonzalez GO, Krisztián G, Damiani G, Krnjevic-Pezic G, Pellerano G, Carretero G, Hunter HJA, Riad H, Oon HH, Boonen HPJ, Moussa IO, García-Doval I, Csányi I, Brajac I, Turchin I, Grozdev I, Weinberg JM, Nicolopoulos J, Wells J, Lambert JLW, Ingram JR, Prinz JC, de Souza Sittart JA, Sanchez JL, Hsiao JP, Castro-Ayarza JR, Maul JT, van den Reek JMPA, Trcko K, Barber K, Reich K, Gebauer KA, Khobzei K, Maul LV, Massari LP, Fardet L, le Cleach L, Misery L, Chandrashekar L, Muresanu LI, Lecluse L, Skov L, F… See abstract for full author list ➔ van Huizen AM, et al. Among authors: gebauer ka. JAMA Dermatol. 2022 May 1;158(5):561-572. doi: 10.1001/jamadermatol.2022.0434. JAMA Dermatol. 2022. PMID: 35353175
115 results